Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 2 1

Status

Active not recruiting 2Recruiting 1

Sponsor Class

OTHER 16NIH 3OTHER_GOV 1INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 2Thoracic 1

Conditions

Pancreatic Neoplasms 1Neoplasm Metastasis 1Lung Neoplasms 1Gallbladder Neoplasms 1Cholangiocarcinoma 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Specimen Handling 329Magnetic Resonance Spectroscopy 238Biopsy 196Nivolumab 57Cyclophosphamide 52X-Rays 49Radiation 47Paclitaxel 47Carboplatin 47Cisplatin 46pembrolizumab 45Taxes 45Immunoglobulin G 45Disulfides 45Platinum 421,2-diaminocyclohexaneplatinum II citrate 42Radiotherapy 38Doxorubicin 36Ipilimumab 32Gemcitabine 32atezolizumab 31CTLA-4 Antigen 31olaparib 28fludarabine 27venetoclax 25Vincristine 25Bevacizumab 25Prednisone 24cabozantinib 23Phantoms, Imaging 23

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
NIH × Radiation Dose Hypofractionation × 90 days × Clear all
NCT04172532 2026-06-02

Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer

National Cancer Institute (NCI)

Phase 1/2 Recruiting
92 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT04068194 2026-05-13

Testing the Combination of New Anti-cancer Drug Peposertib With Avelumab and Radiation Therapy for Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies

National Cancer Institute (NCI)

Phase 1/2 Active not recruiting
103 enrolled
Gastrointestinal

Gallbladder Neoplasms, Neoplasm Metastasis, Cholangiocarcinoma

NCT04310020 2026-05-13

Study of Radiation Therapy Followed by Atezolizumab in Stage II or III Non-small Cell Lung Cancer Patients

National Cancer Institute (NCI)

Phase 2 Active not recruiting
47 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡